NO20065765L - Heart and skeletal muscle inflammation (HSMI) virus - Google Patents

Heart and skeletal muscle inflammation (HSMI) virus

Info

Publication number
NO20065765L
NO20065765L NO20065765A NO20065765A NO20065765L NO 20065765 L NO20065765 L NO 20065765L NO 20065765 A NO20065765 A NO 20065765A NO 20065765 A NO20065765 A NO 20065765A NO 20065765 L NO20065765 L NO 20065765L
Authority
NO
Norway
Prior art keywords
skeletal muscle
hsmi
muscle inflammation
virus
heart
Prior art date
Application number
NO20065765A
Other languages
English (en)
Other versions
NO343278B1 (no
Inventor
Trygve Meum Eliassen
Inge Tom Solbakk
Original Assignee
Pharmaq As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from NO20042454A external-priority patent/NO20042454D0/no
Application filed by Pharmaq As filed Critical Pharmaq As
Priority to NO20065765A priority Critical patent/NO343278B1/no
Publication of NO20065765L publication Critical patent/NO20065765L/no
Publication of NO343278B1 publication Critical patent/NO343278B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/08—Inactivation or attenuation by serial passage of virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12061—Methods of inactivation or attenuation
    • C12N2720/12064—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Den foreliggende oppfinnelse angår et isolert hjerte- og skjelettmuskelbetennelsesvirus (HSMIV) utledet fra fisk; et levende, svekket eller inaktivert HSMIV eller deler av det funksjonelt for vaksineformål, et rekombinant antigen eller vaksine; så vel som DNA, cellelinjer, vaksiner, antistoff, fremgangsmater og anvendelser derav. Oppfinnelsen kan anvendes til å forebygge og diagnostisere hjerte- og skjelettmuskelbetennelse (HSMI) hos fisk.
NO20065765A 2004-06-11 2006-12-14 Isolert hjerte- og skjelettmuskelbetennelsesvirus (HSMIV), fremgangsmåte til fremstilling av HSMIV og medisinsk anvendelse av HSMIV. NO343278B1 (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO20065765A NO343278B1 (no) 2004-06-11 2006-12-14 Isolert hjerte- og skjelettmuskelbetennelsesvirus (HSMIV), fremgangsmåte til fremstilling av HSMIV og medisinsk anvendelse av HSMIV.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
NO20042454A NO20042454D0 (no) 2004-06-11 2004-06-11 Novel fish virus
US57882104P 2004-06-14 2004-06-14
PCT/NO2005/000197 WO2005121325A1 (en) 2004-06-11 2005-06-10 Heart and skeletal muscle inflammation (hsmi) virus
NO20065765A NO343278B1 (no) 2004-06-11 2006-12-14 Isolert hjerte- og skjelettmuskelbetennelsesvirus (HSMIV), fremgangsmåte til fremstilling av HSMIV og medisinsk anvendelse av HSMIV.

Publications (2)

Publication Number Publication Date
NO20065765L true NO20065765L (no) 2007-01-11
NO343278B1 NO343278B1 (no) 2019-01-14

Family

ID=34993270

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065765A NO343278B1 (no) 2004-06-11 2006-12-14 Isolert hjerte- og skjelettmuskelbetennelsesvirus (HSMIV), fremgangsmåte til fremstilling av HSMIV og medisinsk anvendelse av HSMIV.

Country Status (4)

Country Link
CA (1) CA2570050C (no)
GB (1) GB2429711B (no)
NO (1) NO343278B1 (no)
WO (1) WO2005121325A1 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8562802B1 (en) 2006-02-13 2013-10-22 Life Technologies Corporation Transilluminator base and scanner for imaging fluorescent gels, charging devices and portable electrophoresis systems
GB2452363B (en) * 2007-06-28 2012-08-08 Pharmaq As Novel fish pathogen
NO20081040L (no) * 2008-02-27 2009-08-28 Thia Medica As Reduced HSMI mortality
WO2011041789A1 (en) * 2009-10-02 2011-04-07 The Trustees Of Columbia University In The City Of New York Piscine reovirus immunogenic compositions
CA2817933A1 (en) * 2010-11-15 2012-05-24 Pharmaq As New salmon calicivirus isolate
AU2014314140B2 (en) * 2013-08-30 2020-10-22 Pharmaq As Method for propagating a virus
CA3158539A1 (en) 2019-12-16 2021-06-24 Johanna Jacoba Elisabeth Bijlsma Inactivated piscine orthoreovirus vaccine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KONGTORP R.T. ET AL., "Heart and skeletal muscle inflammation in Atlantic salmon, Salmo salar L.: a new infectious disease", Journal of Fish Diseases, vol. 27, nr. 6, 2004, side 351-358, Dated: 01.01.0001 *

Also Published As

Publication number Publication date
WO2005121325A1 (en) 2005-12-22
NO343278B1 (no) 2019-01-14
CA2570050A1 (en) 2005-12-22
GB2429711A (en) 2007-03-07
GB2429711B (en) 2008-05-21
CA2570050C (en) 2013-03-05
GB0625374D0 (en) 2007-01-31

Similar Documents

Publication Publication Date Title
Lycett et al. A brief history of bird flu
Pillet et al. A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults
NO20065765L (no) Heart and skeletal muscle inflammation (HSMI) virus
US11471523B2 (en) Universal vaccines against immunogens of pathogenic organisms that provide organism-specific and cross-group protection
Enjuanes et al. Molecular basis of coronavirus virulence and vaccine development
EA201991911A1 (ru) Способы и композиции для переноса генов по сосудистой сети
NO20054608L (no) Influensavirusvaksine
JP2019510481A (ja) ワクチン開発のための改善されたｂ型インフルエンザウイルス複製
HU229101B1 (en) Dna transfection system for the generation of infectious influenza virus
NO20062044L (no) Piscirickettsia salmonis-antigener og anvendelse derav
TW200732476A (en) Functional influenza virus like particles (VLPs)
AR064642A1 (es) Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
WO2008039267A3 (en) Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
WO2010074575A3 (en) Recombinant classical swine fever virus (csfv) comprising a modified e2 protein and methods for generating said recombinant csfv.
NO20081043L (no) Vaksine for fisk
FR2827605B1 (fr) Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
Tao et al. Identification and genetic characterization of new bovine viral diarrhea virus genotype 2 strains in pigs isolated in China
BR112019018371A2 (pt) flavivírus específico para inseto quimérico
JP2010506926A5 (no)
WO2007005627A3 (en) Tuberculosis antigen detection assays and vaccines
Song et al. Sequence-Independent, Single-Primer Amplification Next-Generation Sequencing of Hantaan Virus Cell Culture–Based Isolates
EA201100674A1 (ru) Вакцина против вируса африканской чумы лошадей
Cox et al. Non‐lethal viral challenge of influenza haemagglutinin and nucleoprotein DNA vaccinated mice results in reduced viral replication
Nogales et al. Live attenuated influenza A virus vaccines with modified NS1 proteins for veterinary use

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 1813 VIKA, 0123 OSLO, NORGE